XTL BiopharmaceuticalsXTLB -2.73%24 FCF Yield % is -30.17 as of Jun. 26, 2026. GuruFocus rates XTLB with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 1,418 Biotechnology companies, XTL Biopharmaceuticals ranks worse than 73.62% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
XTL Biopharmaceuticals FCF Yield % Related Terms
XTL Biopharmaceuticals FCF Yield % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, XTL Biopharmaceuticals's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
XTL Biopharmaceuticals FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, XTL Biopharmaceuticals's FCF Yield % distribution charts can be found below:
* The bar in red indicates where XTL Biopharmaceuticals's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTL Biopharmaceuticals (XTLB) has a FCF Yield % of -30.17 as of Jun. 26, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on XTL Biopharmaceuticals and its competitors. According to the industry distribution chart, XTL Biopharmaceuticals ranks #1044 out of 1418 companies in the Biotechnology industry, placing it in the top 73.6%.
Is XTL Biopharmaceuticals' FCF Yield % too high?
XTL Biopharmaceuticals' current FCF Yield % is -30.17. Based on the distribution chart, XTL Biopharmaceuticals ranks #1044 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, XTL Biopharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does XTL Biopharmaceuticals' FCF Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, XTL Biopharmaceuticals ranks #1044 out of 1418 companies for FCF Yield %. This places XTL Biopharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on XTL Biopharmaceuticals and its competitors. XTL Biopharmaceuticals's current FCF Yield % is -30.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XTL Biopharmaceuticals stock overvalued right now?
XTL Biopharmaceuticals (XTLB) has a current FCF Yield % of -30.17. The current FCF Yield % is -30.17. XTL Biopharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For XTL Biopharmaceuticals (XTLB), the current FCF Yield % is -30.17 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
24GF Score
Get the complete analysis for XTLB
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTLB has been successfully added to your 
